Srinagar, Dec 11: Novo Nordisk India Pvt. Ltd. and Sher-i-Kashmir Institute of Medical Sciences (SKIMS), Soura, have signed a landmark Memorandum of Understanding (MoU) to collaborate on advancing clinical trials in India.
An official spokesperson said this partnership represents a significant stride towards enhancing healthcare research and patient outcomes in the region, combining Novo Nordisk’s expertise in innovative therapeutics with SKIMS’ state-of-the-art medical infrastructure.
The MoU, valid for three years, aims to address unmet medical needs through groundbreaking clinical trials in cardiology, obesity, nephrology, and rare diseases. Novo Nordisk will contribute by building research capacity at SKIMS, providing resources, training, and project-related equipment. SKIMS will expedite the approval process for trials, facilitate patient participation, and ensure patient safety and convenience.
Speaking on the occasion, Vikrant Shrotriya, Managing Director and Corporate Vice President, Novo Nordisk India, stated, “This partnership underscores our commitment to redefining clinical research in India. Together with SKIMS, we aspire to bridge gaps in access to advanced medicines and deliver transformative healthcare solutions for underserved communities.”
Dr. Mohammed Ashraf Ganie, Director, SKIMS, highlighted the collaboration’s significance, saying, “By working with Novo Nordisk, SKIMS aims to elevate clinical research standards in the region and bring world-class healthcare closer to the people of Jammu and Kashmir.”
Spokesperson said the initiative, the first of its kind in the region, reflects a shared vision to drive innovation in clinical research and improve healthcare accessibility. “By combining global expertise with local insights, the partnership sets a benchmark for clinical trials and opens new avenues for transformative healthcare interventions in India”.
Comments are closed.